History

JW Shinyak's steps, which are not afraid of change, never stop.
Taking bold steps towards Clinic Top 10, fulfilling the founding spirit of 'challenging spirit.'

  • 2024

    • ∙  Development of CAR-NK cell therapy with C&C New Drug Research Institute and CureAI USA

    2023

    • ∙  Exclusive domestic sales contract with Galderma Korea for hair loss and onychomycosis treatments
    • ∙  Completed relocation to the new headquarters in Gwacheon, strengthening an 'R&D-centric' management system
    • ∙  Exclusive sales contract with Pierre Fabre, France, for 'hair strengthening cosmetics'

    2022

    • ∙  Obtained ISO37001 certification for the international Anti-Bribery Management System

    2021

    • ∙  Signed a joint research agreement with OncoInsight for 'CAR-M' cancer immunotherapy

    2020

    • ∙  Registered patents in Europe and China for dendritic cell therapies for cancer and autoimmune diseases

    2019

    • ∙  Registered patents in the US and Japan for dendritic cell therapy manufacturing technology

    2018

    • ∙  Registered Japanese patent for dendritic cell manufacturing methods with increased specific gene expression

    2017

    • ∙  CreaVax-BC Phase 1/2 IND approval

    2016

    • ∙  Changed company name to JW Pharmaceutical Co., Ltd.

    2015

    • ∙  Announced Vision 70+5

    2014

    • ∙  CreaVax-HCC Phase 3 IND approval

    2013

    • ∙  CreaVax-RA Phase 2a IND approval

    2012

    • ∙  Launched antigen/cytokine business

    2011

    • ∙  Changed company name to JW New Drug Co., Ltd.
    • ∙  Announced new group CI

Copyright © JW Shinyak,. All rights reserved